BiotechTube

BBI-355 + Erlotinib + Futibatinib + BBI-825

Phase 1Active
1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Triple Negative Breast Cancer (TNBC)

Conditions

Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer

Trial Timeline

Mar 24, 2023 → Mar 31, 2027

NCT ID
NCT05827614

About BBI-355 + Erlotinib + Futibatinib + BBI-825

BBI-355 + Erlotinib + Futibatinib + BBI-825 is a phase 1 stage product being developed by Boundless Bio for Triple Negative Breast Cancer (TNBC). The current trial status is active. This product is registered under clinical trial identifier NCT05827614. Target conditions include Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma.

What happened to similar drugs?

1 of 20 similar drugs in Triple Negative Breast Cancer (TNBC) were approved

Approved (1) Terminated (1) Active (18)
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
🔄Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
🔄Sacituzumab Govitecan-hziy + Pembrolizumab + Paclitaxel + nab-Paclitaxel + Gemcitabine + CarboplatinMerckPhase 3
🔄Pembrolizumab + Sacituzumab tirumotecan + CapecitabineMerckPhase 3
🔄pembrolizumab + capecitabine + eribulin + gemcitabine + vinorelbineMerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05827614Phase 1Active

Competing Products

20 competing products in Triple Negative Breast Cancer (TNBC)

See all competitors
ProductCompanyStageHype Score
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34
Fluzoparib+Paclitaxel + Epirubicin+CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab + Nab paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
31
SHR-1210 + Apatinib +FluzoparibJiangsu Hengrui MedicinePhase 1
29
Cyclophosphamide + Placebo + Doxorubicin + Paclitaxel + Carboplatin + Veliparib + PlaceboAbbViePhase 3
40
Combination of Veliparib + LapatinibAbbViePre-clinical
26
Capivasertib + ItraconazoleAstraZenecaPhase 1
29
Datopotamab Deruxtecan (Dato-DXd) + DurvalumabAstraZenecaPhase 2
42
Paclitaxel + Carboplatin + MEDI4736 + MEDI9447AstraZenecaPhase 1/2
36
KU-0059436 (AZD2281)(PARP inhibitor) + Carboplatin + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + KU-0059436 (AZD2281)(PARP inhibitor) + Paclitaxel + CarboplatinAstraZenecaPhase 1
29
Capivasertib + Paclitaxel + PlaceboAstraZenecaPhase 3
44
Olaparib Oral Product + Olaparib Oral Product in combination with DurvalumabAstraZenecaPhase 2
35
Durvalumab + Capivasertib + Oleclumab + Paclitaxel + Trastuzumab deruxtecan + Datopotamab deruxtecanAstraZenecaPhase 1/2
36